CatalystMarker
← board

CNBX

distress 7/10 · high distress / dilution risk
$0.000%today-86% from 52w high
cnbxpharma.com1 employeesFounded 2004Bethesda, MDBiotechnology
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
+190%

Price & events

-50.0% over 6M
$0.00$0.00$0.00Jan 26Apr 26Jul 26753.8Mfinancing: 8-K material_agreement (2026-03-17)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-50.0%
1M
-75.0%
3M
-50.0%
6M
-82.1%
1Y
-98.7%
2Y
-100.0%
5Y
-100.0%
All

Overview

Market Cap
$160.58K
Volume
20.00K
52 Week Range
$0.00 – $0.00
Total Shares
1.61B
Float Shares
1.61B
% Held by Insiders
0.05%
% Held by Institutions
6.23%
RVOL
0.00x
Beta
0.69

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,605,768,095 · 0 offerings/1y · 0 PIPEs
  • 2026-03-178-Kmaterial_agreement
  • 2025-01-308-Kmaterial_agreement
  • 2024-11-14SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.